A possible trend for greater 12-week PFS rates with tepotinib in patients with MET IHC 3+ status (versus 2+) or MET amplification (versus no MET amplification) was also observed in the Phase 1b/2 second-line trial. 17 In the present study, the low number of patients with MET IHC 3+ staining in the tepotinib arm precludes assessment of the impact of MET IHC status (2+ versus 3+) on the activity of tepotinib versus sorafenib.
← all excerpts
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
1
—
—